Medtronic Looks to Strengthen Spine with Osteotech Purchase
Executive Summary
Medtronic, struggling to hold onto its sizable share of the shrinking spinal market, made a bid for publicly traded Osteotech, a maker of a demineralized bone matrix agent that will broaden the company's regenerative product portfolio.